Shire (SHPG) EPS (Basic) : $15.87 (TTM As of Sep. 2018)

View and export this data going back to 1998. Start your Free Trial

What is Shire EPS (Basic)?

Shire's basic earnings per share (Basic EPS) for the three months ended in Sep. 2018 was $1.77. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2018 was $15.87.

Shire's EPS (Diluted) for the three months ended in Sep. 2018 was $1.74. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2018 was $15.75.

Shire's EPS without NRI for the three months ended in Sep. 2018 was $1.74. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2018 was 15.75.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Shire EPS (Basic) Historical Data

The historical data trend for Shire's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire EPS (Basic) Chart

Shire Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EPS (Basic)

Get a 7-Day Free Trial

3.62

17.42

6.63

1.29

14.13

Shire Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
EPS (Basic)	Get a 7-Day Free Trial															1.83	10.26	1.83	2.01	1.77

Shire EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Shire's Basic EPS for the fiscal year that ended in Dec. 2017 is calculated as

Basic EPS (A: Dec. 2017 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(4271.5	-	0)	/	302.167
	=	14.14

Shire's Basic EPS for the quarter that ended in Sep. 2018 is calculated as

Basic EPS (Q: Sep. 2018 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(537.2	-	0)	/	304.667
	=	1.76

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.87

Shire (NAS:SHPG) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Shire EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Shire's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Shire (SHPG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.shire.com

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Executives

James H Cavanaugh

director

265 HOTHORPE LANE, VILLANOVA PA 19085